Melanoma / Skin

Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(BMS) CA224127 / RELATIVITY-127A Phase 3, Open-label, Randomized, Non-Inferiority Trial for Subcutaneous Formulation of Nivolumab + Relatlimab Fixed-Dose Combination versus Intravenous Administration of Nivolumab + Relatlimab Fixed-Dose Combination in Adult Participants with Previously Untreated Metastatic or Unresectable MelanomaDr Elaine McWhirterOpen to recruitmentNCT05625399
(CCTG) ME.13/STOP-GAPA Randomized Phase III Study of Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP)Dr Elaine McWhirterOpen to recruitmentNCT02821013
(CCTG) ME.15 / MelMarT-IIMelanoma Margins Trial: A Phase III, Multi-centre, Multi-national Randomized Control Trial Investigating 1cm vs 2cm Wide Excision Margins for Primary Cutaneous Melanoma (MelMarT-II)Dr Valerie FrancescuttiOpen to recruitmentNCT03860883
Download PDF